Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2NET 1Genitourinary 1Dermatologic 1

Conditions

Neuroendocrine Tumors 6Gastro-enteropancreatic neuroendocrine tumor 3Carcinoid Tumor 2Prostatic Neoplasms 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Follicular 1Liver Neoplasms 1Hypoglycemia 1Dumping Syndrome 1Carcinoma 1Adenoma, Islet Cell 1Acromegaly 1

Interventions

pasireotide 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pituitary ACTH Hypersecretion × pasireotide × NET × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡